Previous Close | 607.39 |
Open | 612.06 |
Bid | 612.61 x 800 |
Ask | 614.99 x 800 |
Day's Range | 602.52 - 613.15 |
52 Week Range | 536.08 - 747.42 |
Volume | |
Avg. Volume | 713,509 |
Market Cap | 65.869B |
Beta (5Y Monthly) | 0.21 |
PE Ratio (TTM) | 9.80 |
EPS (TTM) | 62.53 |
Earnings Date | Feb 03, 2022 - Feb 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 702.05 |
Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.
Regeneron (REGN) closed at $612.49 in the latest trading session, marking a +0.84% move from the prior day.
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate for transthyretin (ATTR) amyloidosis. Intellia had said that at the highest dose level (1.0mg/kg), six patients had shown a 93% mean reduction in the toxic protein. In the new data, three patients reached the nine-month follow-up point and maintained that level of TTR reduction. Related: Intellia Shares U